Drugs in Dev. Ophthalmology
Phase IV
Israel 
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Bonus BioGroup
Deal Size : $7.4 million
Deal Type : Agreement
Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup
Details : This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Bonus BioGroup
Deal Size : $7.4 million
Deal Type : Agreement
Reset All
